Multimodal quantitative imaging of brain cancer in cultured cells
| dc.contributor.author | Feng, Xin | |
| dc.contributor.author | Muzikansky, Alona | |
| dc.contributor.author | Ross, Alonzo H. | |
| dc.contributor.author | Hamblin, Michael R. | |
| dc.contributor.author | Jermain, Peter R. | |
| dc.contributor.author | Yaroslavsky, Anna N. | |
| dc.date | 2022-08-11T08:09:53.000 | |
| dc.date.accessioned | 2022-08-23T16:47:48Z | |
| dc.date.available | 2022-08-23T16:47:48Z | |
| dc.date.issued | 2019-07-29 | |
| dc.date.submitted | 2019-09-09 | |
| dc.identifier.citation | <p>Biomed Opt Express. 2019 Jul 29;10(8):4237-4248. doi: 10.1364/BOE.10.004237. eCollection 2019 Aug 1. <a href="https://doi.org/10.1364/BOE.10.004237">Link to article on publisher's site</a></p> | |
| dc.identifier.issn | 2156-7085 (Linking) | |
| dc.identifier.doi | 10.1364/BOE.10.004237 | |
| dc.identifier.pmid | 31453007 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/41150 | |
| dc.description.abstract | Fluorescence emission, polarization and subcellular localization of methylene blue (MB) were studied in four cancerous and two normal human brain cell lines. Fluorescence emission and polarization images were acquired and analyzed. The co-localization of MB with mitochondria, lysosomes and nuclei of the cells was evaluated. Glioblastoma cells exhibited significantly higher MB fluorescence polarization compared to normal astrocytes. Preferential accumulation of MB in mitochondria of glioblastoma cells may explain higher fluorescence polarization values in cancer cells as compared to normal. These findings may lead to the development of a quantitative method for the detection of brain cancer in single cells. | |
| dc.language.iso | en_US | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=31453007&dopt=Abstract">Link to Article in PubMed</a></p> | |
| dc.rights | Copyright © 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement, https://www.osapublishing.org/submit/review/pdf/OSACopyTransferOAAgrmnt(2017-09-05).pdf. | |
| dc.subject | brain cancer | |
| dc.subject | glioblastoma cells | |
| dc.subject | cancer cells | |
| dc.subject | detection of brain cancer | |
| dc.subject | Analytical, Diagnostic and Therapeutic Techniques and Equipment | |
| dc.subject | Bioimaging and Biomedical Optics | |
| dc.subject | Cancer Biology | |
| dc.subject | Cell Biology | |
| dc.subject | Cells | |
| dc.subject | Neoplasms | |
| dc.title | Multimodal quantitative imaging of brain cancer in cultured cells | |
| dc.type | Journal Article | |
| dc.source.journaltitle | Biomedical optics express | |
| dc.source.volume | 10 | |
| dc.source.issue | 8 | |
| dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4955&context=oapubs&unstamped=1 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/3939 | |
| dc.identifier.contextkey | 15291867 | |
| refterms.dateFOA | 2022-08-23T16:47:48Z | |
| html.description.abstract | <p>Fluorescence emission, polarization and subcellular localization of methylene blue (MB) were studied in four cancerous and two normal human brain cell lines. Fluorescence emission and polarization images were acquired and analyzed. The co-localization of MB with mitochondria, lysosomes and nuclei of the cells was evaluated. Glioblastoma cells exhibited significantly higher MB fluorescence polarization compared to normal astrocytes. Preferential accumulation of MB in mitochondria of glioblastoma cells may explain higher fluorescence polarization values in cancer cells as compared to normal. These findings may lead to the development of a quantitative method for the detection of brain cancer in single cells.</p> | |
| dc.identifier.submissionpath | oapubs/3939 | |
| dc.contributor.department | Department of Biochemistry and Molecular Pharmacology | |
| dc.source.pages | 4237-4248 |
Files in this item
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitroCholangiocarcinoma (CCA) is a rare biliary tract cancer with a low five-year survival rate and high recurrence rate after surgical resection. Currently treatment approaches include systemic chemotherapeutics such as FOLFIRINOX, a chemotherapy regimen is a possible treatment for severe CCA cases. A limitation of this chemotherapy regimen is its toxicity to patients and adverse events. There exists a need for therapies to alleviate the toxicity of a FOLFIRINOX regimen while enhancing or not altering its anticancer properties. Cold atmospheric plasma (CAP) is a technology with a promising future as a selective cancer treatment. It is critical to know the potential interactions between CAP and adjuvant chemotherapeutics. In this study the aim is to characterize the efficacy of FOLFIRINOX and CAP in combination to understand potential synergetic effect on CCA cells. FOLFIRINOX treatment alone at the highest dose tested (53.8 microM fluorouracil, 13.7 microM Leucovorin, 5.1 microM Irinotecan, and 3.7 microM Oxaliplatin) reduced CCA cell viability to below 20% while CAP treatment alone for 7 min reduced viability to 3% (p < 0.05). An analysis of cell viability, proliferation, and cell cycle demonstrated that CAP in combination with FOLFIRINOX is more effective than either treatment alone at a lower FOLFIRINOX dose of 6.7 microM fluorouracil, 1.7 microM leucovorin, 0.6 microM irinotecan, and 0.5 microM oxaliplatin and a shorter CAP treatment of 1, 3, or 5 min. In conclusion, CAP has the potential to reduce the toxicity burden of FOLFIRINOX and warrants further investigation as an adjuvant therapy.
-
Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a toolOBJECTIVE: To develop a tool for estimating the 10-year risk of death from other causes in men with localized prostate cancer. SUBJECTS AND METHODS: We identified 2,425 patients from the Surveillance Epidemiology and End Results-Medicare Health Outcomes Survey database, age < 80, newly diagnosed with clinical stage T1-T3a prostate cancer from 1/1/1998-12/31/2009, with follow-up through 2/28/2013. We developed a Fine and Gray competing-risks model for 10-year other cause mortality considering age, patient-reported comorbid medical conditions, component scores and items of the SF-36 Health Survey, activities of daily living, and sociodemographic characteristics. Model discrimination and calibration were compared to predictions from Social Security life table mortality risk estimates. RESULTS: Over a median follow-up of 7.7 years, 76 men died of prostate-specific causes and 465 died of other causes. The strongest predictors of 10-year other cause mortality risk included increasing age at diagnosis, higher approximated Charlson Comorbidity Index score, worse patient-reported general health (fair or poor vs. excellent-good), smoking at diagnosis, and marital status (all other vs. married) (all p < 0.05). Model discrimination improved over Social Security life tables (c-index of 0.70 vs. 0.59, respectively). Predictions were more accurate than predictions from the Social Security life tables, which overestimated risk in our population. CONCLUSIONS: We provide a tool for estimating the 10-year risk of dying from other causes when making decisions about treating prostate cancer using pre-treatment patient-reported characteristics.
-
JNK(1/2) represses Lkb(1)-deficiency-induced lung squamous cell carcinoma progressionMechanisms of lung squamous cell carcinoma (LSCC) development are poorly understood. Here, we report that JNK1/2 activities attenuate Lkb1-deficiency-driven LSCC initiation and progression through repressing DeltaNp63 signaling. In vivo Lkb1 ablation alone is sufficient to induce LSCC development by reducing MKK7 levels and JNK1/2 activities, independent of the AMPKalpha and mTOR pathways. JNK1/2 activities is positively regulated by MKK7 during LSCC development. Pharmaceutically elevated JNK1/2 activities abates Lkb1 dependent LSCC formation while compound mutations of Jnk1/2 and Lkb1 further accelerate LSCC progression. JNK1/2 is inactivated in a substantial proportion of human LSCC and JNK1/2 activities positively correlates with survival rates of lung, cervical and head and neck squamous cell carcinoma patients. These findings not only determine a suppressive role of the stress response regulators JNK1/2 on LSCC development by acting downstream of the key LSCC suppresser Lkb1, but also demonstrate activating JNK1/2 activities as a therapeutic approach against LSCC.
